Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Staar Surgical ( (STAA) ) is now available.
On September 26, 2025, STAAR Surgical Company announced an investor presentation and press release regarding a proposed merger with Alcon, highlighting the merger’s potential to maximize value for stockholders. The Board of Directors believes the all-cash offer of $28.00 per share provides a significant premium and is the best strategic path forward, considering the company’s standalone challenges and lack of competing acquisition proposals over the past decade.
The most recent analyst rating on (STAA) stock is a Hold with a $28.00 price target. To see the full list of analyst forecasts on Staar Surgical stock, see the STAA Stock Forecast page.
Spark’s Take on STAA Stock
According to Spark, TipRanks’ AI Analyst, STAA is a Neutral.
Staar Surgical’s overall stock score is primarily impacted by financial struggles, with declining revenues and negative margins being significant concerns. Technical analysis shows bullish momentum, but valuation remains weak due to negative profitability. The earnings call provides some optimism with strategic initiatives, but challenges in China and profitability issues weigh heavily.
To see Spark’s full report on STAA stock, click here.
More about Staar Surgical
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye, primarily focusing on Implantable Collamer Lenses (ICLs) used to treat myopia and other vision issues. Their lenses are made from a proprietary material called Collamer, and the company generates most of its sales from its EVO and EVO+ ICLs.
Average Trading Volume: 1,575,106
Technical Sentiment Signal: Hold
Current Market Cap: $1.33B
Find detailed analytics on STAA stock on TipRanks’ Stock Analysis page.